CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (USD $) In Millions, unless otherwise specified	Apr. 01, 2012		Dec. 31, 2011
Assets
Cash and cash equivalents	$ 2,934		$ 3,182
Short-term investments	21,038		23,270
Accounts receivable, less allowance for doubtful accounts	14,182		13,608
Inventories	7,189		6,969
Taxes and other current assets	9,361		9,441
Assets of discontinued operations and other assets held for sale	159		101
Total current assets	54,863		56,571
Long-term investments	10,632		9,814
Property, plant and equipment, less accumulated depreciation	16,192		16,938
Goodwill	45,252		45,067
Identifiable intangible assets, less accumulated amortization	52,801		53,833
Taxes and other noncurrent assets	5,943		5,779
Total assets	185,683		188,002
Liabilities and Shareholders' Equity
Short-term borrowings, including current portion of long-term debt	5,526	[1]	4,018	[1]
Accounts payable	3,091		3,836
Dividends payable	1		1,796
Income taxes payable	1,930		1,013
Accrued compensation and related items	1,752		2,169
Other current liabilities	14,794		15,237
Total current liabilities	27,094		28,069
Long-term debt	33,543	[2],[3]	34,931	[2],[3]
Pension benefit obligations	6,181		6,355
Postretirement benefit obligations	3,346		3,344
Noncurrent deferred tax liabilities	19,739		19,597
Other taxes payable	6,984		6,886
Other noncurrent liabilities	5,119		6,199
Total liabilities	102,006		105,381
Commitments and Contingencies
Preferred stock	43		45
Common stock	446		445
Additional paid-in capital	71,786		71,423
Employee benefit trusts	(2)		(3)
Treasury stock	(33,519)		(31,801)
Retained earnings	48,124		46,210
Accumulated other comprehensive loss	(3,622)		(4,129)
Total Pfizer Inc. shareholders' equity	83,256		82,190
Equity attributable to noncontrolling interests	421		431
Total shareholders' equity	83,677		82,621
Total liabilities and shareholders' equity	$ 185,683		$ 188,002

[1] The differences between the estimated fair values and carrying values of these financial assets and liabilities not measured at fair value on a recurring basis were not significant as of April 1, 2012 or December 31, 2011. Held-to-maturity debt securities and our short-term and long-term debt fair value are based on Level 2 valuations using a market approach. Fair value measurements for private equity securities are based on Level 3 valuations using a market approach.

[2] Includes foreign currency debt with fair values of $855 million at April 1, 2012 and $919 million at December 31, 2011, which are used as hedging instruments.

[3] The fair value of our long-term debt is $38.6 billion at April 1, 2012 and $40.1 billion at December 31, 2011.